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Heart failure (HF) in hypertrophic cardiomyopathy (HCM) is associated with high 
morbidity and mortality.  Predictors of heart failure, in particular the role of myocardial 
fibrosis and microvascular ischemia remain unclear.  We assessed the predictive value of 
cardiovascular magnetic resonance (CMR) for development of HF in HCM in an 
observational cohort study. 
 
Methods  
Serial patients with HCM underwent CMR, including adenosine first-pass perfusion, left 
atrial (LAV) and left ventricular (LV) volumes indexed to body surface area (i) and late 
gadolinium enhancement (%LGE- as a % of total myocardial mass).  We used a 




A total of 543 patients with HCM underwent CMR, of whom 94 met the composite 
endpoint at baseline. The remaining 449 patients were followed for a median of 5.6 years.  
Thirty nine patients (8.7%) reached the composite endpoint of HF death, cardiac 
transplantation and progression to NYHA class III/IV.  The annual incidence of HF was 
2.0 per 100 person-years, 95% CI (1.6- 2.6).  Age, previous non-sustained ventricular 
tachycardia, LV end-systolic volume indexed to body surface area (LVESVi), LAVi, LV 
ejection fraction, %LGE and presence of mitral regurgitation were significant univariable 
predictors of HF, with LVESVi (Hazard ratio (HR) 1.44, 95% confidence interval (95% 
CI) 1.16-1.78, p=0.001), %LGE per 10% (HR 1.44, 95%CI 1.14-1.82, p=0.002) age (HR 
1.37, 95% CI 1.06-1.77, p=0.02) and mitral regurgitation (HR 2.6, p=0.02) remaining 
independently predictive on multivariable analysis.  The presence or extent of inducible 
perfusion defect assessed using a visual score did not predict outcome (p=0.16, p=0.27 





The annual incidence of HF in a contemporary ambulatory HCM population undergoing 
CMR was low. Myocardial fibrosis and LV end systolic volume were strongly predictive 
of future HF, however CMR visual assessment of myocardial perfusion was not. 
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Patients with hypertrophic cardiomyopathy (HCM) are at risk of heart failure 
(HF)(1,2)(3) and the annual mortality in these patients is ten-fold higher than the general 
HCM population.  Patients with HCM and HF have a high risk of death from both 
progressive pump failure and sudden cardiac death (SCD) (4,5).   
 
There is limited understanding of the mechanisms underlying development of HF in 
HCM. Two areas of active interest are the presence of myocardial replacement fibrosis 
and abnormalities in the microcirculation. Patients with HCM often have abnormal 
myocardial perfusion (6) and recurrent bouts of ischaemia are hypothesised to lead to 
myocardial fibrosis and development of systolic dysfunction (7,8).  Replacement 
myocardial fibrosis has been shown to predict SCD in HCM (9,10) but its relationship to 
HF is not clear. 
 
Cardiovascular magnetic resonance (CMR) allows accurate assessment of left ventricular 
volumes and function, identification and quantification of myocardial fibrosis using late 
gadolinium imaging (LGE), and assessment of myocardial perfusion (11).  We used 
CMR to assess potential mechanistic drivers of HF, in particular, the role of myocardial 
replacement fibrosis and microvascular ischemia.  We hypothesised that the degree of 
myocardial ischemia and replacement fibrosis would predict future HF and aimed to 
assess whether there was added value in routine perfusion imaging for the identification 






Patient recruitment  
Consecutive patients with a diagnosis of HCM seen in the inherited cardiomyopathy 
service or referred to the Royal Brompton Hospital for CMR between December 2003 
and April 2013 were prospectively recruited into a registry.  CMR analysis of perfusion 
using a visual score was performed retrospectively.  All patients provided written 
informed consent for inclusion in the study.  The study was approved by the local 
institutional ethics committee. 
 
All patients met the American Heart Association criteria for diagnosis of HCM, defined 
as a wall thickness of 15mm or greater, or 13-14mm if there was a first degree relative 
with HCM, not explained by another cardiac or systemic disease causing abnormal 
loading conditions(12).   
 
CMR first pass perfusion was initially performed in a pilot HCM cohort and after an 
initial safety phase, recruitment was ramped.  Based on data from nuclear imaging (13) 
and this safety data, dynamic LVOT obstruction was not a contraindication for 
intravenous adenosine infusion.   
We excluded patients who met our HF definition at baseline, known metabolic diseases 
causing a HCM phenocopy, e.g., Anderson-Fabry and Noonan’s syndrome, prior surgical 
myectomy or alcohol septal ablation, and patients with contra-indications to CMR, 
including presence of an implantable cardioverter defibrillator (ICD) or pacemaker.  
Patients with an estimated glomerular filtration rate less than 30 ml/min/1.73 m2 were not 
given gadolinium contrast.  Patients with known significant coronary artery disease, 
defined as >70% stenosis in an epicardial artery of 2mm or greater were excluded from 
analysis. 
 
The predefined primary endpoint was a new major HF event defined as a composite of 
HF death, cardiac transplantation for HF and progression to NYHA class III/IV.  HF 
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death was defined as death associated with unstable, progressive deterioration of pump 
function or symptoms associated with HF.  We additionally collected episodes of HF 
hospitalization, defined as an unplanned admission of greater than 24 hours with new or 
worsening signs of HF, including radiographic evidence of pulmonary edema and/or need 
for intravenous diuretics (14).   
 
The CMR-LGE component of this study was part of a previous LGE outcomes study: 185 
patients were included in a previous outcomes analysis using a composite endpoint 
looking at major adverse cardiovascular events including HF (10).  In the present study, 




CMR scans were performed on a 1.5-T scanner (Siemens Sonata/Avanto, Erlangen, 
Germany) using a standardized protocol as previously described (10).  Patients were 
asked to abstain from dipyridamole, aminophylline, beta blockers or rate-limiting calcium 
channel antagonists for 48 hours and caffeine-containing substances for 24 hours prior to 
imaging.  
 
Myocardial first-pass perfusion imaging was performed using a saturation-recovery 
prepared dual-sequence approach with center-out hybrid echoplanar imaging (EPI) and 
the following typical parameters: fat saturation pulse, composite 90° saturation 
preparation pulse for each slice, 28° readout pulse, repetition time 5.1 ms, echo time 
1.1ms, echo train length 4, field of view 360×288 mm, base resolution 160×160, slice 
thickness 8 mm. Shimming was performed to ensure maximum magnetic field 
homogeneity and minimise off-resonance effects.  Test images were taken to identify any 
artefacts.  Adenosine was infused at 140 mcg/kg/min for 4 minutes and symptoms, heart 
rate and blood pressure were monitored.  At peak hyperaemia, a bolus of gadolinium 
contrast (Magnevist or Gadovist, Bayer-Schering, Berlin, Germany, 0.1 mmol/kg) was 
rapidly injected, followed by a saline bolus.  Three short axis images were acquired every 




LGE imaging was performed using a spoiled gradient-echo segmented k space breath 
hold sequence in long and short axis planes, 10 minutes after injection of gadolinium 
contrast.  Inversion times were optimised to null normal myocardium and images were 
repeated in 2 separate phase-encoding directions to allow exclusion of artifact.  Typical 
sequence parameters were TE 3.1ms, TR 7ms, 8mm slice thickness, 25 degrees flip 
angle, field of view 380x310mm, 25 phase encodes per cardiac cycle.  After 20 minutes, 
rest perfusion imaging was carried out using the same slice positions and gadolinium 
bolus preparation.   
 
 
CMR Image Analysis 
 
Image analysis was performed by experienced operators blinded to clinical outcome.  
Biventricular volumes and mass were measured using dedicated semi-automated software 
(CMRtools, Cardiovascular Imaging Solutions, London, UK) and indexed to body 
surface area (BSA).  Mitral regurgitation was characterized by visual assessment and 
calculation of the regurgitant fraction using stroke volume difference between the left and 
right ventricles.  If LGE was present, the extent was quantified from the short axis stack, 
using commercially available software (CMR42, Circle Cardiovascular Imaging, 
Calgary, Canada).  The endocardial and epicardial borders were manually contoured and 
an area of remote myocardium free of replacement fibrosis and artifact was defined.  
Fibrosis was quantified using the “full width half maximum” (FWHM) technique and 
expressed as a percentage of total left ventricular mass, %LGE (15). 
 
Left atrial (LA) area and length were recorded from the 2- and 4- chamber long axis 
images at end-ventricular systole, just prior to the opening of the mitral valve.  The LA 
length was measured from the midpoint of the mitral valve annulus plane to the top of the 









Where A2CH is the area in the 2-chamber view, A4CH is the area in the 4-chamber view 
and L is the shorter of the two LA length measurements.   
 
CMR visual perfusion scoring 
 
 
An inducible perfusion defect was considered present if a subendocardial or transmural 
area of signal hypointensity was visualised and persisted for 3 frames or more after the 
first arrival of LV myocardial contrast on stress images but not in corresponding rest 
images.  These were distinguished from dark rim artefact due to extent and persistence of 
the defect.  Papillary muscles were excluded from perfusion assessment.  In any patient 
where there was disagreement regarding presence of a perfusion defect, final decision 
was made by consensus.  Two experienced operators blinded to clinical outcome (CER, 
MSV) assessed perfusion used a summed difference score (SDS) (17,18) using the 
ACC/AHA 17 segment model (19), excluding the cardiac apex (segment 17).  Segments 
with LGE enhancement were not excluded from analysis.  Each segment was scored at 
stress and rest as:  0- no defect, 1-inducible perfusion defect <50% of wall thickness, 2- 
inducible perfusion defect>50% of wall thickness (17,18).  The rest score was subtracted 
from the stress score to give the SDS. 
 
Validation of visual perfusion score 
 
In a subset of patients, myocardial blood flow (MBF) was quantitated at rest and at peak 
stress, allowing calculation of the myocardial perfusion reserve index (MPRI) as stress  
MBF/rest MBF according to previously described methods (20,21).   
 
Definition of end points 
 
Events were adjudicated by an independent committee blinded to CMR results.  Mortality 
status was checked at 6 monthly intervals via the UK National Strategic Tracing Service. 
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Cause of death was defined following detailed review of medical records, death 
certification, postmortem data and communication with the patients’ primary care 
physicians and cardiologists.  Patients were followed up by telephone and/or postal 
questionnaire at 6-month intervals and medical records from primary and secondary care 





Baseline characteristics were presented as frequency (percentage) for categorical data and 
mean (standard deviation, SD) for continuous data unless otherwise stated. The 
correlation between the SDS score and quantitative MPRI was assessed using Pearson 
correlation coefficient.  Intra- and inter- operator agreement were assessed using Pearson 
correlation coefficient and Bland Altman analysis, reported as mean difference ±SD of 
the differences.  Continuous variables were dichotomised into groups for generation of 
Kaplan-Meier survival curves.  Kaplan-Meier survival curves were compared using the 
log-rank test. Univariable Cox proportional hazards models were used to test the 
association between baseline covariates and the endpoint.  Variables which were 
significant in the univariable analysis were included in multivariable analyses. 
Multivariable Cox proportional hazards models were used to test the independence of the 
identified predictors of interest. For the combined HF endpoint, data were censored after 
the first component of the composite endpoint.  Results are presented as hazard ratios 
(95% confidence intervals).  A two-tailed p-value <0.05 was considered significant.  
Incidence of new HF was defined as the number of new cases meeting the HF definition 
over the follow up period, divided by the total number of person-years follow-up. 
Incidence was presented as the rate per 100 person-years. Incidence was presented as an 
annualized rate per 100 person-years.  Analyses were performed using Stata 14 








A total of 577 patients were assessed for eligibility, of which 32 were excluded due to 
alternate diagnosis (not HCM) and two due to lack of suitability for CMR (Figure 1).  Of 
the remaining 543, 94 patients met the heart failure endpoint at baseline (17%) and were 
excluded from further analysis, leaving a final study cohort of 449 patients with HCM.  
Patient characteristics are described in Table 1.  Twenty four percent of patients were 
referred via the inherited cardiomyopathy clinic. A third of patients had resting LVOT 
obstruction.   
 
The majority of patients had a perfusion defect at peak adenosine stress (376 patients, 
84%).  The majority of defects were subendocardial and in all coronary territories, 
suggestive of diffuse microvascular disease.  Three patients had a perfusion defect 
corresponding to a coronary artery territory.  Thirty six percent of patients had had recent 
coronary imaging (30% normal coronary angiogram, 5% coronary artery disease with 
prior revascularization and no significant stenoses on most recent imaging, 1% normal 
CT coronary angiogram).  There was no significant correlation between the severity of 
perfusion defect and the %LGE (r=0.05, p=0.34), however patients without a perfusion 
defect had a lower %LGE compared to those with a perfusion defect (median LGE 7.9% 
(IQR 1.1-16.3) vs 13.1% (3.8-24.7, p=0.04).  
 
The datasets generated and/or analysed during the current study are not publicly available 
due to ongoing research but are available from the corresponding author on reasonable 
request. 
 
Validation of visual perfusion score 
 
The SDS and quantitative myocardial perfusion (MPRI) were assessed in a subset of 21 
patients (Figure 2).  Intra-operator agreement for SDS was good (p=0.84, p<0.001) with 
a mean difference (+SD) of 0.1±4.2.  Inter-operator agreement for SDS was also good 
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(p=0.80, p<0.001) with a mean difference (+SD) of 1.7±4.7 (Figure 3).  The correlation 
between SDS and MPRI was reasonable (r=-0.71, p<0.001, Figure 3A).   
   
Heart failure events during follow up 
 
The median follow-up time was 5.6 years (IQR 3.6-8.0 years). Events were censored at 8 
years. Thirty-nine (8.7%) patients met the primary end point: 7 HF deaths (1.6%), 2 heart 
transplants (0.4%) and 30 with symptoms of NYHA class III/IV. This gave a calculated 
annual incidence of HF of 2.0 per 100 person-years, (95% confidence intervals 1.6- 2.6 
person-years).  Of the patients who progressed to NYHA class III/IV, 14 had admission 
with decompensated heart failure requiring intravenous diuresis.  Further details of the 
patients, divided by etiology of heart failure event (HF with reduced EF, HF with 
preserved EF, LVOT obstruction) are described in Table 2.  
 
During follow up, 72 patients (16%) died, including 7 (1.6%) HF deaths and 3 (0.7%) 




Predictors of heart failure endpoint 
 
There were eight predictors of the heart failure end point on univariable analysis (Table 
3).  These were age at baseline, previous non sustained ventricular tachycardia, LVESVi, 
LAVi, LV ejection fraction, presence of LGE>5% of total myocardial, %LGE and 
presence of mitral regurgitation. Presence or extent of inducible perfusion defect did not 
predict outcome (p=0.16, p=0.27 respectively).   On multivariable analysis, four variables 
remained independently predictive (Table 4, Figure 4). 
 
When divided by etiology of HF event, there were no significant predictors of a HF 
endpoint, however sensitivity was limited by low event numbers in the subgroups (Table 
12 
 
2).  Predictors of all-cause death are listed in Table 5.  Predictors of ICD implantation are 








While management of sudden cardiac death has improved in HCM, heart failure remains 
an important cause of both morbidity and mortality.  To date, there have been no 
prospective focused CMR studies that address predictors of HF in HCM.  We report the 
contemporary incidence of heart failure in a large cohort of patients with HCM.  Whilst 
myocardial fibrosis is an important predictor of heart failure, the strongest predictors of 
future heart failure events were %LGE and LVESVi.  The presence and severity of a 
visual perfusion defect as assessed by CMR did not predict HF. 
The incidence of heart failure in our study was similar to earlier studies, which recruited 
patients in 1980s-2000s (5,22,23).  There has been no reduction in heart failure incidence 
despite contemporary management.  Development and testing of novel therapies to 
reduce progression of heart failure therefore remains a key unmet need in HCM.  Our 
data may guide patient selection and trial design for future trials of pharmacotherapy to 
prevent or delay development of heart failure in HCM. 
 
Predictors of heart failure in HCM 
  
In our present study, we focused on potential mechanisms underlying the development of 
HF.  As expected, co-morbidities that predispose to heart failure, including age, diabetes, 
hypercholesterolemia and mitral regurgitation, were predictive of HF outcomes on 
univariable analysis. 
 
Replacement fibrosis increases ventricular stiffness and diastolic dysfunction.  
Progressive myocardial fibrosis may also directly result in reduced ejection fraction, as 
areas of extensive replacement fibrosis will no longer be able to contract.  Over time, 
these changes may lead to LV failure and HF symptoms.  LGE been shown to predict 
development of SCD in HCM and may allow better risk stratification than conventional 
scoring systems (9).  We demonstrated that %LGE is also a predictor of heart failure.  HF 
in HCM is a multifactorial process with distinct phenotypes –hypokinetic evolution, 
restrictive physiology (preserved ejection fraction) and severe LVOT obstruction.  It may 
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be that %LGE has greater predictive value in the first two phenotypes compared to the 
latter.  Our data was not powered to detect such differences but future multicenter studies 
such as HCMR may yield answers.   
 
HCM is associated with structural abnormalities of the mitral valve including 
pathological elongation and leaflet thickening (24).  Mitral regurgitation was predictive 
of HF, independent of LVESVi.  Whether this is causative, resulting from the inability of 
the small volume HCM heart to deal with the increased regurgitant volume, or due to 
association with LVOT obstruction, remains a target for future research.  Of note, resting 
LVOT obstruction was not predictive of HF in our cohort, although we did not have 
complete data on latent LVOT obstruction which is an important limitation. 
 
Perfusion imaging in HCM 
 
Prior work in HCM has demonstrated that inducible perfusion defects are present in over 
half of patients and that these are typically global and subendocardial, representing 
widespread abnormalities in the microcirculation (25,26).  This is in keeping with 
pathology studies demonstrating arteriolar dysplasia and hypertrophy (27).  Interestingly, 
impaired myocardial oxygenation was seen in carriers of HCM mutations prior to 
development of left ventricular hypertrophy, suggesting the microcirculation may be 
affected early in the disease process (28).  Similar to previous work (26), we 
demonstrated that the presence, but not the extent of abnormal myocardial perfusion, was 
associated with higher %LGE.  We have previously demonstrated that a subgroup of 
patients with HCM have regions of myocardium where the stress myocardial blood flow 
is lower than that at rest, which is likely to result in myocardial ischemia (21).  This is 
likely to be one of the drivers of myocardial fibrosis. 
 
Perfusion imaging is not currently recommended for risk stratification in HCM (29). 
While PET studies in a small cohort of patients (n=51) demonstrated that myocardial 
blood flow was a powerful independent predictor of death (7) and heart failure (8), larger 
studies using Thallium SPECT imaging showed no relationship between perfusion 
abnormalities and outcome (30).  It is possible that the strong predictive value of 
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perfusion using PET may reflect a composite measure of myocardial perfusion and 
fibrosis, since perfusion will be reduced in areas of replacement fibrosis (8).  It may also 
suggest that the development of HF in HCM is due to the primary disease process rather 
than propensity to recurrent ischemia.  Unlike PET, visual CMR perfusion and SPECT 
rely on a relative, rather than an absolute assessment of perfusion.  Since perfusion 
abnormalities in HCM are typically diffuse (31), absolute measures of perfusion may be 
required for accurate assessment.  There was moderate agreement between the visual 
SDS score and quantitative CMR perfusion and the predictive value of myocardial 
perfusion may have been different had we used a fully quantitative perfusion method.  
Quantitative perfusion CMR requires specialised sequences and lengthy analysis time 
which would be unfeasible for use in routine clinical practice.   
 
 
Incidence of heart failure compared to earlier studies 
 
Previous studies reported rates of HF in HCM between 5.3 and 14/1000 patient years 
(5,22,23,32).  The incidence in our cohort was slightly higher, which is likely to reflect 
our older patient population, which is similar to the incidence in our cohort (20/1000 
patient years).  Use of medications to reduce development and progression of heart 
failure has been proposed (33) but trial data are lacking. 
 
For trial design, use of surrogate endpoints with probable mechanistic link to HF, may 
improve trial feasibility and cost, since the annual incidence of HF events in HCM is low.  
We suggest that predictors of HF that remain significant on multivariable analysis, and 
have a plausible mechanistic relationship with outcome, such as ventricular replacement 
fibrosis, may be suitable surrogate outcome measures. 
 
In keeping with previous work, we found that patients who subsequently developed HF 
had a larger LV cavity and a larger LA volume at baseline (8,22). Interestingly, we did 
not find presence of LVOT obstruction to be predictive of HF, in contrast to a large prior 
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cohort study (34).  Our findings were in keeping with Harris et al, where patients with 




Myocardial replacement fibrosis is a likely mechanism of progression to heart failure and 
was strongly predictive of future heart failure events.  Visual myocardial perfusion score 
using CMR did not predict future heart failure, however quantitative perfusion using PET 
has previously been predictive.  Development and testing of novel therapies to reduce 
progression of heart failure is an important unmet need in HCM.  Trials are hampered by 
a low event rate.  Use of surrogate endpoints with probable mechanistic link to heart 




Although consecutive patients were enrolled, the study design has potential for referral 
bias. Patients referred for CMR may have been more symptomatic or of clinical concern.  
Patients with an ICD or pacemaker were excluded as these were relative 
contraindications to CMR, which may have excluded high risk patients.  
 
Our heart failure endpoint was largely driven by progression to NYHA class III/IV rather 
than HF death or transplantation.  As event rates of heart failure were low, statistical 
power for multivariable analyses was limited.  
 
We used visual assessment of myocardial perfusion rather than absolute myocardial 
perfusion assessment using CMR.  This is because we did not acquire an arterial input 
function for all patients (20).  Quantitative myocardial perfusion correlated moderately 
with the visual perfusion score and results may have been different had perfusion been 
fully quantitated.  In addition, visual perfusion analysis did not exclude regions of 
replacement fibrosis, which may have altered the findings.  
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T1 mapping was not available at the outset of the study and therefore not performed, 
however would have given a measure of global interstitial fibrosis.  LVOT obstruction 
was assessed at rest but provocation for latent obstruction was not performed. 
 
The mean age of our patients was 60 and there was a higher prevalence of the apical 
variant compared to other studies.  Our population had higher rates of hypertension and 
diabetes than previous studies which are known to cause microvascular disease; however, 
this is reflective of real-life practice.  There may have been unrecognized underlying 
coronary artery disease.  We did not include pediatric patients. We did not systematically 




We prospectively assessed clinical and CMR predictors of heart failure in the HCM 
population.  LV end systolic volume and percentage of late gadolinium enhancement 
were the strongest predictors of heart failure.  CMR visual assessment of myocardial 






CMR – cardiovascular magnetic resonance 
 
HCM – hypertrophic cardiomyopathy 
 
LAVi – left atrial volume indexed to body surface area 
 
LGE – late gadolinium enhancement 
 
LVOT – left ventricular outflow tract 
 
NYHA – New York Heart Association 
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Figure 1: Identification of the study population.   
HF – heart failure, CMR – cardiovascular magnetic resonance.  Significant valvular heart 
disease excluded mitral regurgitation secondary to systolic anterior motion of the mitral 
valve. 
 
577 patients assessed for eligibility
32 excluded:
15 subsequent diagnosis with 
hypertensive heart disease
4 previous alcohol septal ablation




2 Significant valvular heart disease
1 non compaction
2 excluded:
1 contraindication to Gd
1 Claustrophobia
545 assessed for suitability for CMR
543 CMR performed
449 consecutive patients with HCM 
included in main outcome analysis 
39 Heart failure events




Figure 2: Assessment of perfusion defects in HCM.  Perfusion defects were assessed at 
rest (left panel) and adenosine stress (right panel).  Stress perfusion defects were typically 
widespread throughout the 3 coronary territories.  The endocardium was affected more 
than the epicardium.  For visual assessment, perfusion was assessed using the AHA 17 
segment model (excluding the apex) and scored as 0 – no defect, 1 - inducible perfusion 
defect <50% of wall thickness, 2- inducible perfusion defect>50% of wall thickness.  The 
SDS was calculated as the sum of the stress perfusion score minus the sum of the rest 
perfusion score.  In this example, the SDS was (8+12+4)-(0+0+0) =24.  Quantitative 















































Figure 3: A: Agreement between visual perfusion score (SDS) and quantitative MPRI in 
a subset of 21 patients. B: Intra-operator agreement for SDS score.  C: Inter-operator 





















































Figure 4: Kaplan-Meier curves for predictors of heart failure composite endpoint.  










Table 1: Baseline clinical demographics.  Data are presented as mean and standard 
deviation or number (% of total population) as appropriate 
 
Abbreviations: LV – left ventricle, EDV – end diastolic volume, ESV – end systolic volume, LGE – late 
gadolinium enhancement,  EF – ejection fraction, i –indexed to body surface area, NSVT – non sustained 
ventricular tachycardia.  ACEi – angiotensin converting enzyme inhibitor, ARB – angiotensin II receptor 
blocker, NYHA – New York Heart Association Functional classification, CMR – cardiovascular magnetic 
resonance, LVOT – left ventricular outflow tract, SCD – sudden cardiac death, IQR – interquartile range, 
COPD – chronic obstructive pulmonary disease 
  New heart failure No heart failure 
(n=39) (n=410) 
         
Age at baseline CMR, years  63±9 59±14 
Age at diagnosis, years  57±11 53±15 
Sex (% Male)  26 (67%) 308 (75%) 
Apical variant  4 (10%) 66 (16%) 
Atrial fibrillation  3 (8%) 8 (2%) 
  
  
NYHA I 20 (51%)  258 (63%) 
 II 19 (49%) 152 (37%) 




LVOT obstruction >30mmHg 15 (41%) 148 (36%) 
 
 7 (18%) 57 (14%) 
Family history of SCD 
NSVT  7 (18%) 45 (11%) 
Syncope  9 (23%) 66 (16%) 
Wall thickness ≥30mm  4 (10%) 16 (4%) 
    
CMR parameters (median, 
IQR)  
  
Wall Thickness, mm  20 (6) 19 (6) 
LVEDVi ml/BSA  66 (22) 67 (19) 
LVESVi ml/BSA  18 (10) 16 (9) 
LVEF, %  73 (16) 76 (10) 
LGE (% of total myocardial 
mass)  
23 (20) 10 (20) 
LGE (≥5%)  34 (87%) 295 (67%) 
LAVi ml/BSA  65.1 (37.9) 52.9 (24.7) 










Perfusion summed difference 
score 
 14.4 (6.9) 12.8 (8.2) 
Mitral regurgitation       None 18 (46%) 254 (62%) 
 Mild 17 (44%) 127 (31%) 
 >Mild 4 (10%) 29 (7%) 
Medications         
Beta blocker  25(64%) 250 (61%) 
Calcium channel blocker  5 (13%) 70 (17%) 
ACEi/ARB  3 (8%) 70 (17%) 
Aspirin  11 (28%) 82 (20%) 
Warfarin  7 (18%) 12 (3%) 




Co-morbidities         
Coronary artery disease  3 (8%) 41 (10%) 
COPD  0 (0%) 7 (2%) 
Hypercholesterolemia  11 (28%) 61 (15%) 
Diabetes  7 (18%) 32 (8%) 
Hypertension  10 (26%) 97 (24%) 
Stroke  1 (3%) 3 (1%) 
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Table 2: Subclassification of heart failure events by etiology of heart failure.   
 
HFPEF – heart failure with preserved ejection fraction, HFREF – heart failure with reduced ejection 
fraction, LVOT obstruction – heart failure due to severe LVOT obstruction.  NYHA – New York Heart 
Association, HF – heart failure 
 
Heart failure event HFPEF HFREF 
LVOT 
obstruction 
 n= 13 n=20 n=6 
Heart failure death 2 4 1 
Referral for cardiac 
transplantation 
0 2 0 
Progression to NYHA class III/IV 11 14 3 
Decompensated HF requiring 
admission with diuresis 




Table 3: Univariable predictors of a heart failure event.  
 
Abbreviations: FH – family history, NSVT – non sustained ventricular tachycardia, LV – left 
ventricle, EDV – end diastolic volume, ESV – end systolic volume, LGE – late gadolinium enhancement,  i 
–indexed to body surface area, NYHA – New York Heart Association Functional classification, CMR – 
cardiovascular magnetic resonance, LVOT – left ventricular outflow tract, SCD – sudden cardiac death 
*patients with no LGE enhancement did not have any HF events, therefore <5% LGE was used as the 






HR (95% CI) P 
Age (per 10 years) 1.32 (1.04, 1.67) 0.02 
Age at diagnosis (per 10 years)  1.16 (0.93, 1.45) 0.18 
BSA (kg/m2) 1.79 (0.41, 7.87) 0.44 
Female 1.52 (0.78, 2.95) 0.22 
Apical 0.47 (0.17, 1.32) 0.15 
Atrial fibrillation 2.86 (0.88, 9.28) 0.08 
LVOT gradient (≥30mmHg at rest) 1.40 (0.74, 2.66) 0.30 
Family history of SCD 1.31 (0.60, 2.85) 0.50 
NSVT 2.23 (1.02, 4.86) 0.04 
Unexplained syncope 1.45 (0.69, 3.06) 0.33 
Max wall thickness ≥30mm 2.34 (0.83, 6.59) 0.11 
CMR parameters   
0.32 
0.07 
Max wall thickness (mm) 1.03 (0.97, 1.09) 
LVEDVi (per 10ml/BSA) 1.19 (0.99, 1.45) 
LVESVi (per 10ml/BSA) 1.51 (1.23, 1.85) <0.0001 
LAVi (per 10ml/BSA) 1.11 (1.00, 1.22) 0.04 
LVEF 0.95 (0.92, 0.98) 0.001 
LGE (per 10%) 1.57 (1.27, 1.93) <0.0001 
Presence of LGE (≥5% of myocardial mass)* 3.99 (1.56, 10.22) 0.004 
Perfusion defect 2.09 (0.74, 5.88) 0.16 
Perfusion summed difference score 1.02 (0.98, 1.06) 0.27 
Mitral regurgitation   
None 1.00 0.03 
Mild 2.13 (1.10, 4.14) 0.27 
Moderate/Severe 2.13 (0.72, 6.31)  
  







Table 4: Multivariable predictors of a new heart failure event.  Abbreviations as per 
Table 2. 
 
 HR (95% CI) P-value 
LVESVi (per 10ml/BSA) 1.44 (1.16, 1.78) 0.001 
Mitral regurgitation   
      None Reference group 
0.02       Mild 1.94 (0.99, 3.81) 
      Moderate/Severe 2.55 (0.84, 7.70) 
LGE (per 10%) 1.44 (1.14, 1.82) 0.002 






Table 5: Univariable predictors of all-cause mortality 
 
 HR (95% CI) P 
Age (per 10 years) 2.45 (1.85, 3.26) <0.001 
LAVi (per 10) 1.10 (1.01, 1.21) 0.03 
Unexplained syncope 2.06 (1.06, 4.01) 0.03 
Hypertension 0.37 (0.14, 0.94) 0.04 




Table 6: Univariable predictors of ICD implantation 
 OR (95% CI) P 
NSVT 9.43 (4.84, 18.37) <0.001 
Unexplained syncope 3.36 (1.74, 6.50) <0.001 
Family history of SCD 2.60 (1.31, 5.15) 0.006 
Age (per 10 years) 0.80 (0.64, 0.99) 0.04 
 
 
